Consolidated interim report 1 January – 30 September 2023
Consolidated interim report 1 January – 30 September 2023
16 November 2023
Company Announcement no. 44
Key points (nine-month report ended 30 September 2023)
On 16 November 2023, the Board of Directors and Executive Management of Pharma Equity Group A/S ("PEG" or "the Group") have considered and approved the consolidated interim report for the period 1 January – 30 September 2023 (“Q1-Q3 2023 report”). The figures have neither been audited nor reviewed.
The transaction with Reponex Pharmaceuticals A/S
As further described in both the Q1 and the H1 2023 interim reports, the consolidated financial statements have been prepared applying the rules for reverse take-over where Reponex has been identified as the acquirer for accounting purposes.
New Board of Directors
At the extraordinary general meeting on 2 November 2023, the company's Board of Directors was supplemented by two highly qualified members with extensive experience in, among other things, finance, international relations, and investor communication. The two new members are Omar S. Qandeel and Martin Engell-Rossen.
Omar S. Qandeel is an international businessman who focuses primarily on social impact investments and project development together with Asian, European and Middle Eastern companies and governments.
Martin Engell-Rossen is best known as Denmark's leading political strategist. He has a strong background as former chief of staff in the Prime Minister's Office and special adviser to Prime Minister Mette Frederiksen.
Martin Engell-Rossen was most recently Senior Vice President for Group Communication & Sustainability at Danfoss.
The Board of Directors now consists of Christian Vinding Thomsen (Chairman), Martin Engell-Rossen (Vice Chairman), Omar S. Qandeel, Lars Gundorph and Peter Vilmann.
Products and patents
Development and testing of the six drug candidates of the subsidiary Reponex Pharmaceuticals A/S (Reponex) has continued in Q3 2023 and with reference to Company Announcement No. 37 of 15 August 2023 and Company Announcement No. 41 of 31 October 2023 the Company have received grant of patent from United States Patent and Trademark (USPTO) for a method of threating a topical wound-healing composition. This application describes a method of treating a chronic wound by the topical application of a hydrogel containing granulocyte-macrophage colony-stimulating factor (GM-CSF), sucralfate and hyaluronan to accelerate wound healing. The patent is valid until 2039.
Furthermore, with reference to Company Announcement No 42 of 31 October 2023, The European Patent Office (EPO) has issued an "Intention To Grant" for EU patent applications numbers 15724673.7 and 19701467.3.
The former application, which pertains to the wound-healing candidate RNX-022, describes a method for treating chronic wounds by applying a hydrogel containing granulocyte-macrophage colony-stimulating factor (GM-CSF), sucralfate, and hyaluronan to accelerate wound healing.
The latter application concerns the colorectal cancer candidate RNX-051 and describes a method for suppressing bacterial layers (biofilms) protecting the cancerous tumor or adenomas (potential tumors) from the body's immune system in the colon or rectum.
A Notice of “Intention to Grant" indicates that the EPO intends to issue the patents after certain standard procedural steps are completed, with the patents expected to be granted within 2 months, valid until 2035 and 2039, respectively.
Marketing and communication
PEG and Reponex intensified marketing and communication in several areas in Q3 2023. A completely new communication and marketing strategy has been rolled out, which has, among other things, resulted in several video presentations about Pharma Equity Group and about the Reponex Corporate Identity and about the repositioning strategy for the various drug candidates. Reference is made to our webpage Video presentations - Pharma Equity Group.
The new strategy has, in November 2023, also resulted in release of a new logo of PEG and a new homepage. In relation to the drug candidates, 4 patient stories have been recorded on film, developed to increase the knowledge of PEG and Reponex.
For the nine-months period ended 30 September 2023 Pharma Equity Group A/S realized a loss after tax of DKK 11.6 million, which is in line with expectations for the period. As of 30 September 2023, equity equals DKK 51.3 million.
We maintain the previously announced expectations for 2023, a loss before tax in the range of DKK 18 million to DKK 22 million for the Group. The outlook does not reflect any potential gains/losses relating to the upcoming settlement of the Portinho S.A receivable.
Receivable from Portinho S.A.
The Group’s receivable from Portinho S.A has a principal outstanding amount of EUR 9.55 million with a carrying value per 30 September 2023 of DKK 64 million.
Since 1 July 2023, the Company's Board of Directors and Executive Management have intensified their already close dialogue with the management of Portinho S.A. Based on this dialogue and the information received from Portinho S.A., it is expected that the receivable will be repaid shortly and probably no later than December 2023. New financial agreement terms have been agreed, which means that from 1 July 2023 the receivable will bear interest at 2% per quarter instead of 0.5%. See also Company Announcement No. 39 from 25 September 2023.
The Company has provided security to a number of financial creditors, including Sparekassen Sjælland-Fyn A/S, Nykredit A/S and private lenders, in the receivables from Portinho S.A. The due dates for the debts secured by the Portinho receivables will follow the concluded resolution plan.
As a result of the postponement of the payment from Portinho S.A., the Company has been working on possible bridge financing together with existing shareholders. Bridge financing as of 16 November 2023 has been created for DKK 6.5 million to support the company's operations for the foreseeable future. The intention is to obtain loan commitments in the level of DKK 20 million.
Contact person – Investor Relations
On the Company’s website www.pharmaequitygroup.com further information and all published announcements can be found.
Inquiries regarding relations with investors and the stock market can be directed to:
Thomas Kaas Selsø, CEO, Phone: +45 4022 2114 E-mail: firstname.lastname@example.org
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury5.12.2023 04:41:56 CET | Press release
With its targeted multimodal approach, NeuroAiD™II offers a broad range of therapeutic benefits to TBI patients.NeuroAiD™II was well-tolerated by TBI patients with a favourable safety profile. SINGAPORE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Moleac announced promising results from the SAMURAI double-blind study in patients with mild traumatic brain injury (mTBI) receiving a 6-month course of NeuroAiD™II. In the study, the NeuroAiD™II group showed significant improvement in their post-concussion symptoms, quality of life and mood, compared to those in the placebo group. Presented by Professor Valery Feigin at the World Congress of Neurology, last October in Montreal, these results expand the list of therapeutic benefits of NeuroAiD™II observed in previous clinical trials conducted on TBI patients, and confirm its favourable safety profile1, 2, 3. In the SAMURAI study, mTBI patients underwent a series of tests assessing various types of impairments and their recovery over time. For cognition
Nokia comments on AT&T vendor plans5.12.2023 03:30:00 CET | Press release
Nokia Corporation Stock Exchange Release 5 December 2023 at 4:30 EET Nokia comments on AT&T vendor plans Espoo, Finland – Nokia has a wide-ranging relationship with AT&T, supplying products and services across wireless, wireline and other network technologies, alongside similar relationships with other major North American network operators. Nokia is aware of AT&T’s plans to commit to an Open RAN deployment in collaboration with other vendors over the next five years. As a result, Nokia now expects revenue from AT&T in Mobile Networks will decrease over the next 2-3 years. AT&T accounted for 5-8% of Mobile Networks net sales year-to-date in 2023. The already announced action Nokia is taking to reduce its cost base is expected to partially mitigate the impact of AT&T’s decision. Nokia expects Mobile Networks to remain profitable over the coming years but this decision would delay the timeline of achieving double digit operating margin by up to 2 years. Nokia has invested heavily in the
Canadian Government Awards New Funding to General Fusion5.12.2023 02:00:00 CET | Press release
RICHMOND, Canada, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Today, General Fusion announced that Canada’s Strategic Innovation Fund (SIF) has awarded CA$5 million to support research and development to advance the company’s Magnetized Target Fusion (MTF) demonstration at its Richmond headquarters. Called LM26, this ground-breaking machine will progress major technical milestones required to commercialize zero-carbon fusion power by the early to mid-2030s. The funds are an addition to the existing contribution agreement with SIF, to support the development of General Fusion’s transformational technology. Fusion energy is the ultimate clean energy solution. It is what powers the sun and stars. It’s the process by which two light nuclei merge to form a heavier one, emitting a massive amount of energy. By 2100, the production and export of the Canadian industry’s fusion energy technology could provide up to $1.26 trillion in economic benefits to Canada. Additionally, fusion could completely offset
LeddarTech and Prospector Capital Corp. Announce Effectiveness of Registration Statement and December 13, 2023 Extraordinary General Meeting to Approve Business Combination4.12.2023 23:30:00 CET | Press release
QUEBEC CITY, Dec. 04, 2023 (GLOBE NEWSWIRE) -- LeddarTech Inc.® (“LeddarTech” or the “Company”), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology for ADAS and AD, and Prospector Capital Corp. (“Prospector”) (NASDAQ: PRSR, PRSRU, PRSRW), a publicly traded special-purpose acquisition company led by former Qualcomm President Derek Aberle and chaired by former Qualcomm Vice Chairman Steve Altman, today announced that on December 4, 2023 the U.S. Securities and Exchange Commission (the “SEC”) declared effective the Registration Statement on Form F-4, as amended, filed by LeddarTech Holdings Inc. (“Newco”) in connection with the previously announced proposed business combination (the “Business Combination”). The filing can be viewed in its entirety on the SEC’s website at www.sec.gov. Prospector also commenced mailing the definitive proxy statement/prospectus on December 4, 2023, which was included in the Reg
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20234.12.2023 22:30:00 CET | Press release
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version